Literature DB >> 28317077

De novo cancer in patients on dialysis and after renal transplantation: north-western Italy, 1997-2012.

Valentina Mazzucotelli1, Pierluca Piselli2, Diana Verdirosi3, Claudia Cimaglia4, Giovanni Cancarini1,5, Diego Serraino3, Silvio Sandrini1.   

Abstract

BACKGROUND: Kidney transplant recipients (KTR) are known to have a higher risk of cancer than the general population, especially of malignancies related to oncogenic viral infections. This study assessed the incidence of de novo malignancies (DNMs) in patients receiving kidney transplantation and in dialysis patients (DP) on the waiting list for transplantation at the same centre. The aim was to quantify the contribution of post-transplant immunosuppression to the underlying risk of developing a DNM in dialysis patients on the waiting list for kidney transplant.
METHODS: Cancer incidence rates were computed using the Kaplan-Meier product-limit method. The number of DNMs observed in both groups was compared to the expected incidence in the general Italian population through calculation of the standardized incidence ratios (SIR) and their 95% confidence intervals (CI). To identify risk factors, incidence rate ratios (IRR) and 95% CIs were computed using Poisson regression analysis. The comparison of incidence rates between the two cohorts was also performed using age standardized incidence rates (ASR) and their ratio (age standardized rate ratio, ASRR).
RESULTS: In 4858 person-years (PYs) of observation, 75 out of 735 KTR were diagnosed with DNM: 57 solid neoplasms, 13 post-transplant lymphoproliferative disorders (PTLD), and 12 Kaposi sarcomas (KS). The overall incidence was 17.5 cases/103 PYs, resulting in a 2.1-fold increased risk. Twenty-four out of 912 DP, over a follow-up of 2400 PYs, were diagnosed with a solid neoplasm, but none had PTLD or KS. The use of induction therapy after transplant was associated with a significant increased risk of KS (IRR: 3.52; 95% CI 1.04-11.98, p < 0.05). ASRR for all cancers and for solid cancers only was 1.84- and 1.19-fold higher in KTR, respectively, than in the general population. The overall incidence in DP was 10.0 cases/103 PYs, with a 1.6 significantly increased cancer risk compared to the general population.
CONCLUSION: Our study confirms the increased risk of cancer after transplantation and during dialysis, but showed that virus-related cancers only occur after post-transplant immunosuppression.

Entities:  

Keywords:  Cancer risk; Dialysis; Immunosuppression; Kidney transplantation; Oncogenic viruses

Mesh:

Year:  2017        PMID: 28317077     DOI: 10.1007/s40620-017-0385-y

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  17 in total

Review 1.  Post renal transplantation Kaposi's sarcoma: a review of its epidemiology, pathogenesis, diagnosis, clinical aspects, and therapy.

Authors:  S M Hosseini-Moghaddam; A Soleimanirahbar; T Mazzulli; C Rotstein; S Husain
Journal:  Transpl Infect Dis       Date:  2012-02-09       Impact factor: 2.228

Review 2.  Malignancy after transplantation.

Authors:  Joseph F Buell; Thomas G Gross; E Steve Woodle
Journal:  Transplantation       Date:  2005-10-15       Impact factor: 4.939

Review 3.  De novo malignancies after organ transplantation: focus on viral infections.

Authors:  P Piselli; G Busnach; L Fratino; F Citterio; G M Ettorre; P De Paoli; D Serraino
Journal:  Curr Mol Med       Date:  2013-08       Impact factor: 2.222

4.  Cancer in patients on dialysis for end-stage renal disease: an international collaborative study.

Authors:  P Maisonneuve; L Agodoa; R Gellert; J H Stewart; G Buccianti; A B Lowenfels; R A Wolfe; E Jones; A P Disney; D Briggs; M McCredie; P Boyle
Journal:  Lancet       Date:  1999-07-10       Impact factor: 79.321

5.  Cancer risk in patients on dialysis and after renal transplantation.

Authors:  S A Birkeland; H Løkkegaard; H H Storm
Journal:  Lancet       Date:  2000-05-27       Impact factor: 79.321

6.  Lymphomas after solid organ transplantation: a collaborative transplant study report.

Authors:  Gerhard Opelz; Bernd Döhler
Journal:  Am J Transplant       Date:  2004-02       Impact factor: 8.086

7.  Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study.

Authors:  Marina T van Leeuwen; Angela C Webster; Margaret R E McCredie; John H Stewart; Stephen P McDonald; Janaki Amin; John M Kaldor; Jeremy R Chapman; Claire M Vajdic; Andrew E Grulich
Journal:  BMJ       Date:  2010-02-11

8.  Variations in registration of skin cancer in the United Kingdom.

Authors:  R G Goodwin; S A Holme; D L Roberts
Journal:  Clin Exp Dermatol       Date:  2004-05       Impact factor: 3.470

9.  CKD and the risk of incident cancer.

Authors:  William T Lowrance; Juan Ordoñez; Natalia Udaltsova; Paul Russo; Alan S Go
Journal:  J Am Soc Nephrol       Date:  2014-05-29       Impact factor: 10.121

10.  Immunosuppression and other risk factors for lip cancer after kidney transplantation.

Authors:  Marina T van Leeuwen; Andrew E Grulich; Stephen P McDonald; Margaret R E McCredie; Janaki Amin; John H Stewart; Angela C Webster; Jeremy R Chapman; Claire M Vajdic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-03       Impact factor: 4.254

View more
  9 in total

1.  How safe are organs from deceased donors with neoplasia? The results of the Italian Transplantation Network.

Authors:  Albino Eccher; Letizia Lombardini; Ilaria Girolami; Francesca Puoti; Gianluigi Zaza; Giovanni Gambaro; Amedeo Carraro; Giovanni Valotto; Luca Cima; Luca Novelli; Desley Neil; Umberto Montin; Aldo Scarpa; Matteo Brunelli; Alessandro Nanni Costa; Antonia D'Errico
Journal:  J Nephrol       Date:  2019-01-02       Impact factor: 3.902

Review 2.  Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?

Authors:  Jan Lerut; Samuele Iesari; Maxime Foguenne; Quirino Lai
Journal:  Transl Gastroenterol Hepatol       Date:  2017-10-12

3.  Hypertensive nephropathy and cancer: Is it the hypertension, the nephropathy, or both?

Authors:  Sabine Karam
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-05-24       Impact factor: 3.738

4.  Increased cancer risk in patients undergoing dialysis: a population-based cohort study in North-Eastern Italy.

Authors:  Martina Taborelli; Federica Toffolutti; Stefania Del Zotto; Elena Clagnan; Lucrezia Furian; Pierluca Piselli; Franco Citterio; Loris Zanier; Giuliano Boscutti; Diego Serraino
Journal:  BMC Nephrol       Date:  2019-03-28       Impact factor: 2.388

5.  Cancer patterns and association with mortality and renal outcomes in non-dialysis dependent chronic kidney disease: a matched cohort study.

Authors:  Rajkumar Chinnadurai; Emma Flanagan; Gordon C Jayson; Philip A Kalra
Journal:  BMC Nephrol       Date:  2019-10-22       Impact factor: 2.388

6.  Distribution and association of cancer with mortality in end-stage renal disease patients receiving dialysis.

Authors:  Rajkumar Chinnadurai; Emma Flanagan; Philip A Kalra
Journal:  J Nephrol       Date:  2019-09-25       Impact factor: 3.902

7.  Cancer Risks in Solid Organ Transplant Recipients: Results from a Comprehensive Analysis of 72 Cohort Studies.

Authors:  Zhenyu Huo; Caichen Li; Xin Xu; Fan Ge; Runchen Wang; Yaokai Wen; Haoxin Peng; Xiangrong Wu; Hengrui Liang; Guilin Peng; Run Li; Danxia Huang; Ying Chen; Ran Zhong; Bo Cheng; Shan Xiong; Weiyi Lin; Jianxing He; Wenhua Liang
Journal:  Oncoimmunology       Date:  2020-11-29       Impact factor: 8.110

Review 8.  Current Status of Malignant Tumors after Organ Transplantation.

Authors:  Bairu Shen; Zhuofei Cen; Minghua Tan; Changshan Song; Xuhui Wu; Jiaqing Wang; Minqian Huang
Journal:  Biomed Res Int       Date:  2022-02-18       Impact factor: 3.411

9.  Tumor Recurrence and Graft Survival in Renal Transplant Recipients with a History of Pretransplant Malignancy: A Matched Pair Analysis.

Authors:  Felix Becker; Anne-Sophie Mehdorn; Vasilios Getsopulos; Katharina Schütte-Nütgen; Stefan Reuter; Barbara Suwelack; Andreas Pascher; Jens G Brockmann; Ralf Bahde
Journal:  J Clin Med       Date:  2021-05-27       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.